Across TCGA pan-cancer cohorts, IFRD2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IFRD2 data layer compared with 20 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher IFRD2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated IFRD2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, CCRCC, and PDAC are the cancer types where IFRD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.829	0.443	.006	30	view →
CCRCC	OS	Median	All	0.921	1.000	.033	4	view →
PDAC	OS	Tertile	All	0.996	0.721	.016	3	view →
HNSC	OS	Median	III,IV	1.000	0.449	.043	2	view →
LSCC	OS	Median	II,III,IV	0.916	0.752	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: IFRD2 tumor-vs-normal RNA expression · all IFRD2 data types